Idorsia
Magdalena Birker has a strong background in molecular biology, with extensive experience in cardiovascular and fibrosis biology. Magdalena began their career at INSERM U271 in Lyon, where they completed their PhD from 1997 to 2002. Magdalena then joined Actelion in 2002, where they held various positions including Postdoctoral Researcher, Lab Head of Molecular Biology, Senior Lab Head of Molecular Biology, and Associate Director and Principal Scientist of Cardiovascular and Fibrosis Biology. In 2017, Magdalena Birker joined Idorsia Pharmaceuticals Ltd as Associate Director and Principal Scientist, specializing in cardiovascular and fibrosis biology.
Magdalena Birker's education history includes attending the University of Gdansk, Gdański Uniwersytet Medyczny (Medical University of Gdańsk), and INSA Lyon - Institut National des Sciences Appliquées de Lyon. However, the specific degrees or fields of study are not provided. In addition to their formal education, Magdalena has obtained certifications in Workshop Problemsolving (Typ A) from MIKA - Management-, Informations- und Kommunikationsausbildung, Good Clinical Practices from the Swiss Tropical and Public Health Institute, Management Training from Krauthammer, and Medical Affairs in Medicines Development from the GMDP Academy. The year of completion or acquisition for some certifications is not mentioned.
Idorsia
4 followers
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.